Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study|
|Citation:||Blood, 2012; 119(15):3512-3522|
|Publisher:||American Society of Hematology|
|I-Ming Chen, Richard C. Harvey, Charles G. Mullighan, Julie Gastier-Foster, Walker Wharton, Huining Kang, Michael J. Borowitz, Bruce M. Camitta, Andrew J. Carroll, Meenakshi Devidas, D. Jeanette Pullen, Debbie Payne-Turner, Sarah K. Tasian, Shalini Reshmi, Catherine E. Cottrell, Gregory H. Reaman, W. Paul Bowman, William L. Carroll, Mignon L. Loh, Naomi J. Winick, Stephen P. Hunger and Cheryl L. Willman|
|Abstract:||As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. Whereas very high CRLF2 expression was found in 17.5% of cases, only 51.4% of high CRLF2 expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2 expressors, whereas IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression, and IKZF1 lesions were associated with relapse-free survival. Within HR ALL, only MRD and CRLF2 expression predicted a poorer relapse-free survival; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, ALL.|
|Keywords:||Trials, childhood leukemia|
|Rights:||© 2012 by The American Society of Hematology|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.